[Low molecular-weight heparin (clexane) in the prevention of thrombotic events in patients with malignancies].
The basic links of the hemostatic system and the markers of intravascular thrombogenesis were studied, by using an automatic STA Compact analyzer in 80 patients with locomotor tumors. The patients were divided into 2 groups: 1) 50 patients received clexane, 40 mg, 12 hours before and within 7-18 days after surgery (a study group); 2) 30 patients underwent only nonspecific prevention of thrombotic events (a control group). Postoperatively, hypercoagulation was shown to persist long (up to 18 days) in patients with locomotor tumors. Clexane used in the pre- and postoperative periods within 18-20 days was effective in reducing the rate of intravascular blood coagulation, preventing thrombotic events, and failing to cause hemorrhages.
Somonova
O V
OV
Madzhuga
A V
AV
Elizarova
A L
AL
Sel'chuk
V Iu
VIu
Zubrikhina
G N
GN
Bokhian
A Iu
AIu
D017984:Enoxaparin / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000150:complications* / Q000601:surgery; D011182:Postoperative Care; D011183:Postoperative Complications / Q000517:prevention & control*; D011300:Preoperative Care; D020246:Venous Thrombosis / Q000150:complications / Q000517:prevention & control*
D017984:Enoxaparin; D006495:Heparin, Low-Molecular-Weight